Compare Jumia Technologies AG - ADR (JMIA) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jumia Technologies AG - ADR vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Jumia Technologies AG - ADR trades at $5.74 (market cap $773.69M), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M). The key difference: Maravai LifeSciences Holdings Inc. Class A Common Stock is the larger of the two by market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, Jumia Technologies AG - ADR nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Jumia Technologies AG - ADR for 29 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| JMIA | MRVI | |
|---|---|---|
Market Cap | $773.69M | $977.37M |
Volume | 1,611,098 | 2,742,564 |
Sector | Consumer Cyclical | Health |
52-Week High | $14.60 | $9.00 |
52-Week Low | $5.69 | $2.83 |
Typical Hold Time | 29 Days | 0 Days |
Enterprise Value | $739.34M | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JMIA trades at $5.91, down 3.27% with a bearish technical signal. The company shows improving fundamentals with revenue growth to $189M in 2025 and narrowing losses, though it remains unprofitable with a -27.54% net margin. Recent news highlights operational improvements and a $50M capital raise, while analysts maintain a strong buy consensus with a $12 price target representing significant upside potential.
JMIA presents a high-risk, high-reward opportunity with improving operational metrics and path to profitability, but faces execution risks in African markets. The stock trades at a discount to analyst targets but requires successful execution on cost controls and market expansion to justify valuation. Current technical weakness contrasts with fundamental improvement trends.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Jumia Technologies AG - ADR
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates most of its revenue from the West Africa segment.
Read more on JMIA →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
